Baron Health Care Fund highlighted Veradermics, Incorporated in its second-quarter 2026 investor letter, noting the clinical-stage biopharmaceutical company's VDPHL01 candidate demonstrated robust hair growth in a Phase 3 trial for male pattern hair loss. Up to 63% of male patients reported improved hair coverage compared to just 13% on placebo. The fund awaits data from a second Phase 3 study in males and the first Phase 2 data in females, both expected in the second half of 2026. If approved by the FDA, VDPHL01 would be the first FDA-approved oral treatment in several decades for a condition affecting 80 million Americans. Veradermics shares closed at $101.89 on August 3, 2026, with a market capitalization of $4.26 billion.
Veradermics, IncorporatedPhase 3 data shows 63% hair coverage improvement, a key milestone for VDPHL01.
Hims Hers Health Inc